How much of the 2024 revenue growth was sustainable versus one-time?

About $22 million of FY2024 precision oncology revenue was a non-recurring, out-of-period benefit from better-than-expected cash collections on prior-year claims. Excluding it, management's implied 2025 growth framework is 19-20% total revenue growth versus 15-16% reported. Investors should evaluate 2024 organic growth as somewhat lower than the headline 31%.

What drove the improvement in the net loss in 2024?

The primary driver was the absence of the $83.4 million non-recurring legal accrual recorded in 2023. The company also cited a $37.7 million improvement in operating loss excluding that accrual, the absence of a $29.1 million 2023 impairment, and an $18.3 million rise in interest income. These were partly offset by a $124.1 million negative swing in fair value adjustments on its Lunit, Inc. stake.

What is the impact of the February 2025 convertible note exchange?

Guardant exchanged $659.3 million of 0% 2027 notes for $600.0 million of new 1.25% notes due 2031, extending maturity and reducing near-term principal. Transaction costs were about $12.4 million. It also repurchased $45.0 million of common stock at $46.09 per share. Pro forma, cash and marketable securities fall to about $886.8 million, and the remaining 2027 notes total $490.7 million. The new notes carry a cash interest cost of 1.25%, compared with 0% previously.

How is the Shield screening business expected to affect financial results in 2025?

Management expects Shield to generate $25-30 million in screening revenue on 45,000-50,000 tests in 2025, and about $200 million of screening net cash burn. Non-GAAP operating expenses are guided up 8-9% to $815-825 million, mainly to fund the commercial ramp. Management expects the rest of the business, excluding screening, to reach free cash flow breakeven in Q4 2025, so overall results depend heavily on the pace of Shield adoption.

What are the main 2025 financial targets for investors to track?

Key 2025 guidance includes total revenue of $850-860 million; oncology revenue growth of about 15% (about 20% excluding the 2024 non-recurring item); oncology clinical volume growth of about 25%; biopharma and data revenue growth in the low double digits; non-GAAP gross margin of 62-63%; and free cash flow burn of $225-235 million. Quarterly progress on clinical volume, Shield test volume, and the cash burn trajectory will be the most useful indicators.

GH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.

Guardant Health (GH) reported Q4 and full-year 2024 results on February 20, 2025, with total revenue of $739.0 million^a for FY2024, up 31% year over year, and Q4 revenue of $201.8 million, up 30%.

Precision oncology revenue grew 34% for the year to $687.9 million^b, though management disclosed an approximately $22 million non-recurring, out-of-period revenue benefit from better-than-expected cash collections on prior-year claims, which flatters the growth rate. Clinical oncology volume grew 20% for the year, and biopharma test volume grew 35%. Shield, the company's blood-based colorectal cancer screening test, began contributing revenue after FDA approval, generating $5.1 million in 2024 and roughly 6,400 screening tests in Q4 alone.

Profitability improved mainly because 2023 included an $83.4 million^c non-recurring legal accrual. GAAP net loss narrowed to $436.4 million ($3.56 per share) from $479.4 million, and non-GAAP net loss improved to $247.2 million from $352.3 million. Free cash flow burn narrowed to $274.9 million from $345.5 million.

Balance sheet activity was significant: in February 2025 the company exchanged $659.3 million^d of its 0% 2027 convertible notes for $600.0 million of new 1.25% notes due 2031, and repurchased $45.0 million of stock at $46.09 per share. Pro forma cash and marketable securities would be about $886.8 million, against $490.7 million of remaining 2027 notes.

For 2025, management guided to total revenue of $850-860 million (15-16% growth, or 19-20% excluding the 2024 non-recurring item), screening revenue of $25-30 million on 45,000-50,000 Shield tests, non-GAAP gross margin of 62-63%, non-GAAP operating expenses of $815-825 million, and free cash flow burn of $225-235 million, including about $200 million of screening cash burn. Management expects the non-screening business to reach free cash flow breakeven in Q4 2025.

02—Key points

Key Highlights

FY2024 total revenue of $739.0M, up 31% YoY; Q4 2024 revenue of $201.8M, up 30%
FY2024 precision oncology revenue up 34% to $687.9M, but includes ~$22M non-recurring, out-of-period collections benefit
Clinical oncology volume grew 20% and biopharma tests grew 35% in FY2024; management guides clinical volume acceleration to ~25% in 2025
Shield launched commercially: $5.1M screening revenue in 2024 and ~6,400 tests in Q4; 2025 guidance of 45,000-50,000 tests and $25-30M screening revenue
GAAP net loss narrowed to $436.4M from $479.4M, mainly from lapping the $83.4M 2023 legal accrual; non-GAAP net loss $247.2M vs. $352.3M
Free cash flow burn improved to $274.9M from $345.5M; 2025 guidance of $225-235M burn, including ~$200M from screening
Convertible note exchange: $659.3M of 2027 notes retired for $600M of 1.25% notes due 2031; pro forma cash and securities ~$886.8M

03—Questions

Frequently Asked Questions

How much of the 2024 revenue growth was sustainable versus one-time?
About $22 million of FY2024 precision oncology revenue was a non-recurring, out-of-period benefit from better-than-expected cash collections on prior-year claims. Excluding it, management's implied 2025 growth framework is 19-20% total revenue growth versus 15-16% reported. Investors should evaluate 2024 organic growth as somewhat lower than the headline 31%.
What drove the improvement in the net loss in 2024?
The primary driver was the absence of the $83.4 million non-recurring legal accrual recorded in 2023. The company also cited a $37.7 million improvement in operating loss excluding that accrual, the absence of a $29.1 million 2023 impairment, and an $18.3 million rise in interest income. These were partly offset by a $124.1 million negative swing in fair value adjustments on its Lunit, Inc. stake.
What is the impact of the February 2025 convertible note exchange?
Guardant exchanged $659.3 million of 0% 2027 notes for $600.0 million of new 1.25% notes due 2031, extending maturity and reducing near-term principal. Transaction costs were about $12.4 million. It also repurchased $45.0 million of common stock at $46.09 per share. Pro forma, cash and marketable securities fall to about $886.8 million, and the remaining 2027 notes total $490.7 million. The new notes carry a cash interest cost of 1.25%, compared with 0% previously.
How is the Shield screening business expected to affect financial results in 2025?
Management expects Shield to generate $25-30 million in screening revenue on 45,000-50,000 tests in 2025, and about $200 million of screening net cash burn. Non-GAAP operating expenses are guided up 8-9% to $815-825 million, mainly to fund the commercial ramp. Management expects the rest of the business, excluding screening, to reach free cash flow breakeven in Q4 2025, so overall results depend heavily on the pace of Shield adoption.
What are the main 2025 financial targets for investors to track?
Key 2025 guidance includes total revenue of $850-860 million; oncology revenue growth of about 15% (about 20% excluding the 2024 non-recurring item); oncology clinical volume growth of about 25%; biopharma and data revenue growth in the low double digits; non-GAAP gross margin of 62-63%; and free cash flow burn of $225-235 million. Quarterly progress on clinical volume, Shield test volume, and the cash burn trajectory will be the most useful indicators.

04—Continue

← View all 8-K filings